Building a Compliant Regenerative Marketing Kit for Your Clinic

Why distributor and clinic marketing language is under active FDA scrutiny

FDA treats a company's website, social media, and marketing materials as evidence of a product's intended use. In 2026, FDA issued warning letters to distributors of private-label Wharton's jelly and exosome products that referenced specific diseases or conditions on their websites and social channels, with letters dated February, May, and August 2026.

The same reasoning applies to clinics. A clinic's own marketing about a product it purchases can create regulatory exposure independent of what the supplier says, because FDA and FTC both look at the claim as made to the public, not just at who manufactured the product.

What a claim-safe marketing kit actually controls for

A compliant kit does not avoid talking about the product category. It avoids three specific things: naming a disease, condition, or symptom the product is said to help with; describing an outcome, result, or comparative superiority; and implying a regulatory status the product does not have, such as FDA approval or clearance.

FTC's health claims guidance requires that any claim about a health benefit be supported by competent and reliable scientific evidence appropriate to the claim. The simplest way to meet that bar is to not make benefit claims in consumer-facing material at all, and instead describe what the product is and how it is sourced, processed, and documented.

Language patterns to build around, and patterns to retire

Marketing copy can describe category, format, sourcing, and documentation without describing effect. Phrases like 'a perinatal tissue allograft offered under the supplier's HCT/P framework' or 'documentation available to verified accounts' describe the product honestly without promising an outcome.

• Retire: any disease or symptom name paired with the product as something it helps, supports, or is used for
• Retire: 'proven,' 'clinically proven,' 'guaranteed,' 'most effective,' 'results,' 'FDA approved/cleared/licensed'
• Retire: before/after framing, patient testimonials, or outcome claims of any kind
• Build around: sourcing and screening description, processing and testing description, documentation available on request
• Build around: a visible disclosure that the product is not FDA approved or licensed for any disease or condition

Reviewing a kit before it goes out, and what to do with state law questions

Before publishing, a workable review pass is to read every sentence and ask: does this name a condition, promise an effect, or imply a federal approval status that does not exist. If yes to any, the sentence needs to be rewritten around what is documented, not what is implied.

Some states have passed laws addressing physician use of non-FDA-approved cell-based products, such as Florida's SB 1768, effective July 2025, which addresses physician use of certain products in specific specialties under informed consent. Provisions like this govern physician conduct within that state and do not change federal FDA requirements on the product itself, so marketing claims still need to clear the federal bar regardless of state-level permissions.

Clinics running paid advertising should also know that major ad platforms restrict this category directly. Google Ads policy prohibits advertising speculative or experimental cell therapies in the United States, independent of what a clinic's own website says.